Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/metabolismo , Inflamación/metabolismo , Sinoviocitos/metabolismo , Animales , Antígenos CD/efectos de los fármacos , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/metabolismo , Artritis Reumatoide/patología , Variación Biológica Poblacional , Progresión de la Enfermedad , Fosfatasa 1 de Especificidad Dual/efectos de los fármacos , Fosfatasa 1 de Especificidad Dual/metabolismo , Fibroblastos/metabolismo , Glucocorticoides/farmacología , Humanos , Inflamación/fisiopatología , Macrófagos/metabolismo , Ratones , Modelos Animales , Receptor de Melanocortina Tipo 1/agonistas , Receptor Notch3/metabolismo , Receptores de Superficie Celular/efectos de los fármacos , Receptores de Superficie Celular/metabolismoRESUMEN
Repeated exposure to mild TBI (mTBI) has been linked to an increased risk of Alzheimer's disease (AD), chronic traumatic encephalopathy (CTE) and other neurodegenerative diseases. Some pathological features typically observed in AD have been found in postmortem brains of TBI and CTE, hence treatments tested for AD have a potential to be effective against r-mTBI outcomes. Neuroinflammation may present a possible answer due to its central role both in acute brain injury and in chronic degenerative-like disorders. Our previous studies have shown that drug nilvadipine, acting as an inhibitor of spleen tyrosine kinase (SYK), is effective at reducing inflammation, tau hyperphosphorylation and amyloid production in AD mouse models. To demonstrate the effect of nilvadipine in the absence of age-related variables, we introduced the same treatment to young r-mTBI mice. We further investigate therapeutic mechanisms of nilvadipine using its racemic properties. Both enantiomers, (+)-nilvadipine and (-)-nilvadipine, can lower SYK activity, whereas (+)-nilvadipine is also a potent L-type calcium channel blocker (CCB) and shown to be anti-hypertensive. All r-mTBI mice exhibited increased neuroinflammation and impaired cognitive performance and motor functions. Treatment with racemic nilvadipine mitigated the TBI-induced inflammatory response and significantly improved spatial memory, whereas (-)-enantiomer decreased microgliosis and improved spatial memory but failed to reduce the astroglial response to as much as the racemate. These results suggest the therapeutic potential of SYK inhibition that is enhanced when combined with the CCB effect, which indicate a therapeutic advantage of multi-action drugs for r-mTBI.
Asunto(s)
Conmoción Encefálica/fisiopatología , Bloqueadores de los Canales de Calcio/farmacología , Nifedipino/análogos & derivados , Aprendizaje Espacial/efectos de los fármacos , Memoria Espacial/efectos de los fármacos , Quinasa Syk/antagonistas & inhibidores , Animales , Antígenos CD/efectos de los fármacos , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/metabolismo , Conmoción Encefálica/metabolismo , Conmoción Encefálica/psicología , Proteínas de Unión al Calcio/efectos de los fármacos , Proteínas de Unión al Calcio/metabolismo , Proteína Ácida Fibrilar de la Glía/efectos de los fármacos , Proteína Ácida Fibrilar de la Glía/metabolismo , Inflamación/metabolismo , Ratones , Proteínas de Microfilamentos/efectos de los fármacos , Proteínas de Microfilamentos/metabolismo , Nifedipino/farmacología , Fosforilación , Prueba de Desempeño de Rotación con Aceleración Constante , Aprendizaje Espacial/fisiología , Memoria Espacial/fisiología , Quinasa Syk/efectos de los fármacos , Quinasa Syk/metabolismoRESUMEN
Cigarette smoking and opium use are risk factors for coronary artery disease (CAD). It has been known that scavenger receptors such as CD36 and CD68 play critical roles in the pathogenesis of CAD. CD9, as a member of the tetraspanin, has been shown to interact with scavenger receptors. The aim of this study was to investigate the effects of these risk factors on expression levels of CD9, CD36, and CD68 on the THP-1 cell line. The THP-1 cell line treated with cigarette smoke extract (CSE( and opium, both individually and combinatory, in 24 h incubation. The protein and mRNA levels of CD9, CD36, and CD68 were evaluated by flow cytometry and quantitative reverse transcription-Polymerase Chain Reaction (qRT-PCR) techniques, respectively. CD36 and CD68 mRNA and protein expression levels were significantly increased in the cells treated with cigarette smoke extract compared to the control (p<0.001 in mRNA expression levels and p=0.016 and p=0.012 in protein expression levels, respectively). The CSE increased the level of CD9 protein expression compared to the control group (p=0.041) on the human macrophage cell line THP-1. No significant differences were observed in the CD9, CD36, and CD68 gene expression and at the protein levels between opium-treated THP-1 cells and controls. In conclusion, cigarettes by increasing the levels of CD36, CD68, and CD9 can be a risk factor in the development of many inflammatory diseases, including cardiovascular diseases, chronic obstructive pulmonary disease (COPD) and lung carcinoma.
Asunto(s)
Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Nicotiana/toxicidad , Opio/toxicidad , Extractos Vegetales/toxicidad , Humo/efectos adversos , Antígenos CD/biosíntesis , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/biosíntesis , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Antígenos CD36/biosíntesis , Antígenos CD36/efectos de los fármacos , Humanos , Fumar/efectos adversos , Células THP-1 , Tetraspanina 29/biosíntesis , Tetraspanina 29/efectos de los fármacos , Productos de Tabaco/efectos adversosRESUMEN
The macrophage activation markers, soluble CD163 (sCD163) and soluble mannose receptor (sMR), are associated with liver disease severity and prognosis. We aimed to investigate macrophage activation reflected by sMR and sCD163 in patients with mild and severe paracetamol (PCM) intoxication and effects of antidote treatment in patients and healthy controls. We measured sMR and sCD163 levels by in-house enzyme-linked immunosorbent assays in two independent prospective cohorts of PCM overdosed patients: 49 patients with early mild PCM overdose from Aarhus University Hospital and 30 patients with severe acute liver injury included at the Royal Infirmary of Edinburgh. Furthermore, we investigated sMR and sCD163 in 14 healthy controls during N-acetylcysteine treatment. Within the mild PCM cohort, patients with elevated alanine transaminase on admission had significantly higher levels of sCD163 compared with patients with normal alanine transaminase (2.92[2.00-5.75] versus 1.29[1.02-1.69] mg/L, p = .009), whereas sMR showed no significant difference. In patients with acute liver injury, both markers were markedly higher compared to the mild PCM cohort (sCD163: 10.73[5.79-14.62] versus 1.34[1.06-1.96], p < .001; sMR: 0.80[0.63-1.14] versus 0.18[0.14-0.25], p < .001). Antidote treatment significantly reduced sCD163 levels in both PCM overdosed patients and healthy controls. In conclusion, macrophage activation assessed by the levels of sMR and sCD163 is associated with the degree of liver injury in patients with PCM intoxication and is ameliorated by antidote treatment, suggesting macrophage involvement in PCM-induced liver injury.
Asunto(s)
Acetaminofén/envenenamiento , Analgésicos no Narcóticos/envenenamiento , Antígenos CD/sangre , Antígenos de Diferenciación Mielomonocítica/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Lectinas Tipo C/sangre , Activación de Macrófagos , Lectinas de Unión a Manosa/sangre , Receptores de Superficie Celular/sangre , Adulto , Antídotos/uso terapéutico , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Biomarcadores/sangre , Estudios de Casos y Controles , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Sobredosis de Droga/terapia , Femenino , Humanos , Lectinas Tipo C/efectos de los fármacos , Modelos Lineales , Masculino , Receptor de Manosa , Lectinas de Unión a Manosa/efectos de los fármacos , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Receptores de Superficie Celular/efectos de los fármacos , Adulto JovenRESUMEN
PRRSV can replicate for months in lymphoid organs leading to persistent host infections. Porcine bone marrow comprises two major monocyte subsets, one of which expresses CD163 and CD169, two receptors involved in the entry of PRRSV in macrophages. In this study, we investigate the permissiveness of these subsets to PRRSV infection. PRRSV replicates efficiently in BM CD163+ monocytes reaching titers similar to those obtained in alveolar macrophages, but with a delayed kinetics. Infection of BM CD163- monocytes was variable and yielded lower titers. This may be related with the capacity of BM CD163- monocytes to differentiate into CD163+ CD169+ cells after culture in presence of M-CSF. Both subsets secreted IL-8 in response to virus but CD163+ cells tended to produce higher amounts. The infection of BM monocytes by PRRSV may contribute to persistence of the virus in this compartment and to hematological disorders found in infected animals such as the reduction in the number of peripheral blood monocytes.
Asunto(s)
Células de la Médula Ósea/virología , Médula Ósea/inmunología , Monocitos/virología , Virus del Síndrome Respiratorio y Reproductivo Porcino/fisiología , Animales , Antígenos CD/efectos de los fármacos , Antígenos CD/inmunología , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/inmunología , Médula Ósea/virología , Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/inmunología , Células Cultivadas , Interacciones Huésped-Patógeno/inmunología , Interleucina-8/inmunología , Interleucina-8/metabolismo , Factor Estimulante de Colonias de Macrófagos/genética , Factor Estimulante de Colonias de Macrófagos/farmacología , Monocitos/clasificación , Monocitos/inmunología , Síndrome Respiratorio y de la Reproducción Porcina/virología , Virus del Síndrome Respiratorio y Reproductivo Porcino/inmunología , Receptores de Superficie Celular/efectos de los fármacos , Receptores de Superficie Celular/inmunología , Lectina 1 Similar a Ig de Unión al Ácido Siálico/efectos de los fármacos , Lectina 1 Similar a Ig de Unión al Ácido Siálico/inmunología , Porcinos , Replicación ViralRESUMEN
AIMS: Dipeptidyl peptidase-4 inhibitor (DPP-4i) is commonly used worldwide for the treatment of type 2 diabetes mellitus. In addition to its hypoglycemic activity, DPP-4i might have anti-inflammatory effects. In this study we examined the effects of DPP-4i on the serum levels of soluble CD163 (sCD163), a marker for activated macrophages, in individuals with type 2 diabetes mellitus. We compared these anti-inflammatory effects with those of α glucosidase inhibitor (αGI). METHODS: Japanese patients with type 2 diabetes mellitus who were stably maintained on ≤2mg/day glimepiride alone were recruited and randomly assigned to receive additional sitagliptin (n=37) or αGI (n=37). Levels of sCD163 were measured before the addition and after a 24-week treatment period. RESULTS: Addition of sitagliptin significantly reduced the serum sCD163 (632 vs. 575ng/mL, p<0.05), while αGI did not display this effect (624 vs. 607ng/mL). The changes in levels of sCD163 were not related to changes in either HbA1c or body mass index (BMI). CONCLUSIONS: Our results suggested that DPP-4i might exert anti-inflammatory effects in individuals with type 2 diabetes mellitus, which are independent of its effects on glycemia and BMI.
Asunto(s)
Antígenos CD/sangre , Antígenos de Diferenciación Mielomonocítica/sangre , Diabetes Mellitus Tipo 2/sangre , Inhibidores de Glicósido Hidrolasas/uso terapéutico , Hipoglucemiantes/uso terapéutico , Macrófagos/efectos de los fármacos , Receptores de Superficie Celular/sangre , Fosfato de Sitagliptina/uso terapéutico , Anciano , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Biomarcadores/sangre , Glucemia/efectos de los fármacos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Receptores de Superficie Celular/efectos de los fármacos , Compuestos de Sulfonilurea/uso terapéuticoRESUMEN
Simultaneous targeting of multiple tumor-associated antigens (TAAs) in cancer immunotherapy is presumed to enhance tumor cell selectivity and to reduce immune escape.The combination of B lymphoid marker CD19 and myeloid marker CD33 is exclusively present on biphenotypic B/myeloid leukemia cells. Triplebody 33-3-19 binds specifically to both of these TAAs and activates T cells as immune effectors. Thereby it induces specific lysis of established myeloid (MOLM13, THP-1) and B-lymphoid cell lines (BV173, SEM, Raji, ARH77) as well as of primary patient cells. EC50 values range from 3 pM to 2.4 nM. In accordance with our hypothesis, 33-3-19 is able to induce preferential lysis of double- rather than single-positive leukemia cells in a target cell mixture: CD19/CD33 double-positive BV173 cells were eliminated to a significantly greater extent than CD19 single-positive SEM cells (36.6% vs. 20.9% in 3 hours, p = 0.0048) in the presence of both cell lines. In contrast, equivalent elimination efficiencies were observed for both cell lines, when control triplebody 19-3-19 or a mixture of the bispecific single chain variable fragments 19-3 and 33-3 were used. This result highlights the potential of dual-targeting agents for efficient and selective immune-intervention in leukemia patients.
Asunto(s)
Antígenos de Neoplasias/efectos de los fármacos , Antineoplásicos/farmacología , Inmunoterapia/métodos , Leucemia Bifenotípica Aguda , Anticuerpos de Cadena Única/farmacología , Citotoxicidad Celular Dependiente de Anticuerpos/efectos de los fármacos , Citotoxicidad Celular Dependiente de Anticuerpos/inmunología , Antígenos CD19/inmunología , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/inmunología , Humanos , Lectina 3 Similar a Ig de Unión al Ácido Siálico/inmunologíaRESUMEN
Mice exposed to standard (SE) or enriched environment (EE) were transplanted with murine or human glioma cells and differences in tumour development were evaluated. We report that EE exposure affects: (i) tumour size, increasing mice survival; (ii) glioma establishment, proliferation and invasion; (iii) microglia/macrophage (M/Mφ) activation; (iv) natural killer (NK) cell infiltration and activation; and (v) cerebral levels of IL-15 and BDNF. Direct infusion of IL-15 or BDNF in the brain of mice transplanted with glioma significantly reduces tumour growth. We demonstrate that brain infusion of IL-15 increases the frequency of NK cell infiltrating the tumour and that NK cell depletion reduces the efficacy of EE and IL-15 on tumour size and of EE on mice survival. BDNF infusion reduces M/Mφ infiltration and CD68 immunoreactivity in tumour mass and reduces glioma migration inhibiting the small G protein RhoA through the truncated TrkB.T1 receptor. These results suggest alternative approaches for glioma treatment.
Asunto(s)
Ambiente , Glioma/patología , Células Asesinas Naturales/inmunología , Macrófagos/inmunología , Microglía/inmunología , Juego e Implementos de Juego , Animales , Antígenos CD/efectos de los fármacos , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/metabolismo , Factor Neurotrófico Derivado del Encéfalo/inmunología , Factor Neurotrófico Derivado del Encéfalo/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Glioma/inmunología , Glioma/mortalidad , Humanos , Interleucina-15/inmunología , Interleucina-15/farmacología , Activación de Macrófagos , Macrófagos/efectos de los fármacos , Ratones , Microglía/efectos de los fármacos , Invasividad Neoplásica , Trasplante de Neoplasias , Estimulación Física , Receptor trkB/efectos de los fármacos , Receptor trkB/metabolismo , Medio Social , Tasa de Supervivencia , Carga Tumoral/efectos de los fármacos , Proteínas de Unión al GTP rho/efectos de los fármacos , Proteínas de Unión al GTP rho/metabolismo , Proteína de Unión al GTP rhoARESUMEN
INTRODUCTION: M2 (alternatively activated) macrophages are known to participate in wound healing and tissue repair. This study aimed to analyze the temporospatial changes in the distribution and density of M2 macrophage-associated molecule-expressing cells after pulpotomy with mineral trioxide aggregate (MTA) in rat molars to ascertain the role played by M2 macrophages in the healing of MTA-capped pulp tissue. METHODS: The maxillary first molars of 8-week-old Wistar rats were pulpotomized and capped with MTA. After 1-14 days, the teeth were examined after hematoxylin-eosin staining or immunoperoxidase staining of CD68 (a general macrophage marker) and M2 macrophage markers (CD163 and CD204). The density of positively stained cells was enumerated in the surface and inner regions (0-100 µm and 300-400 µm, respectively, from the wound surface). RESULTS: MTA capping initially caused mild inflammatory changes and the formation of a degenerative layer followed by progressive new matrix formation and calcified bridging. At 1-2 days, CD68-, CD163-, and CD204-positive cells started to accumulate beneath the degenerative layer, and the density of these cells was significantly higher in the surface region than in the inner region (P < .05). From 7 days onward, the 3 types of cells displayed an almost normal distribution beneath the newly formed dentinlike matrix. CONCLUSIONS: After the pulpotomy of rat molars with MTA, M2 macrophage-associated molecule-expressing cells transiently accumulated beneath the degenerative layer under the MTA. This suggests that M2 macrophages participate in the initial phases of the healing of MTA-capped pulp tissue.
Asunto(s)
Compuestos de Aluminio/farmacología , Compuestos de Calcio/farmacología , Activación de Macrófagos/efectos de los fármacos , Macrófagos/efectos de los fármacos , Óxidos/farmacología , Materiales de Recubrimiento Pulpar y Pulpectomía/farmacología , Pulpotomía/métodos , Silicatos/farmacología , Animales , Antígenos CD/análisis , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/análisis , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Recuento de Células , Dentina Secundaria/efectos de los fármacos , Combinación de Medicamentos , Odontoblastos/efectos de los fármacos , Ratas , Ratas Wistar , Receptores de Superficie Celular/análisis , Receptores de Superficie Celular/efectos de los fármacos , Receptores Depuradores de Clase A/análisis , Receptores Depuradores de Clase A/efectos de los fármacos , Factores de Tiempo , Cicatrización de Heridas/efectos de los fármacosRESUMEN
INTRODUCTION: Matrix metalloproteinase (MMP)-3 is a member of the MMP family that degrades the extracellular matrix. Application of MMP-3 to injured pulp tissue induces angiogenesis and wound healing, but its anti-inflammatory effects are still unclear. Here, we evaluated the anti-inflammatory functions of MMP-3 in vitro and in vivo. METHODS: Nitric oxide and inflammatory mediator synthesis in macrophages activated by lipopolysaccharide (LPS) was measured in the presence or absence of MMP-3. The mouse Mmp3 (mMmp3) expression vector containing full length cDNA sequence of mMmp3 or cDNA sequence of mMmp3 missing the signal peptide and pro-peptide regions was transfected to RAW264, a mouse macrophage cell line, and NO synthesis and inflammatory mediator expression were evaluated. Pulpal inflammation was histologically and immunohistochemically evaluated in a rat model of incisor pulpitis induced by the application of LPS for 9 hours in the presence or absence of MMP-3. RESULTS: NO and pro-inflammatory mediator synthesis promoted by LPS was significantly down-regulated by MMP-3 in vitro. The full length of mMmp3 down-regulated the LPS-induced NO synthesis and chemical mediator mRNA expression, however the mMmp3 missing the signal peptide failed to block the NO synthesis induced by LPS. The numbers of major histocompatibility complex class II+ and CD68+ cells, which infiltrated into the rat incisor pulp tissues in response to the topical application of LPS, were significantly decreased by the application of MMP-3 in vivo. CONCLUSIONS: These results indicate that MMP-3 possesses anti-inflammatory functions, suggesting its potential utility as an anti-inflammatory agent for pulpal inflammation.
Asunto(s)
Antiinflamatorios/farmacología , Regulación hacia Abajo/efectos de los fármacos , Mediadores de Inflamación/metabolismo , Macrófagos/efectos de los fármacos , Metaloproteinasa 3 de la Matriz/farmacología , Pulpitis/inmunología , Animales , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Línea Celular , Células Cultivadas , Quimiocina CCL2/análisis , Ciclooxigenasa 2/efectos de los fármacos , Antígenos de Histocompatibilidad Clase II/efectos de los fármacos , Interleucina-17/análisis , Interleucina-1beta/efectos de los fármacos , Interleucina-6/análisis , Lipopolisacáridos/farmacología , Masculino , Ratones , Óxido Nítrico/análisis , Pulpitis/prevención & control , Ratas , Ratas WistarRESUMEN
Siglecs (sialic acid immunoglobulin-like lectins) are members of the immunoglobulin gene family that contain sialoside binding N-terminal domains. They are cell surface proteins found predominantly on cells of the immune system. Among them, Siglec-8 is uniquely expressed by human eosinophils and mast cells, as well as basophils. Engaging this structure with antibodies or glycan ligands results in apoptosis in human eosinophils and inhibition of release of preformed and newly generated mediators from human mast cells without affecting their survival. Pro-apoptotic effects are also seen when its closest functional paralog, Siglec-F, on mouse eosinophils is similarly engaged in vitro, and beneficial effects are observed after administration of Siglec-F antibody using models of eosinophilic pulmonary and gastrointestinal inflammation in vivo. Siglec-8 targeting may thus provide a means to specifically inhibit or deplete these cell types. Cell-directed therapies are increasingly sought after by the pharmaceutical industry for their potential to reduce side effects and increase safety. The challenge is to identify suitable targets on the cell type of interest, and selectively deliver a therapeutic agent. By targeting Siglec-8, monoclonal antibodies and glycan ligand-conjugated nanoparticles may be ideally suited for treatment of eosinophil and mast cell-related diseases, such as asthma, chronic rhinosinusitis, chronic urticaria, hypereosinophilic syndromes, mast cell and eosinophil malignancies and eosinophilic gastrointestinal disorders.
Asunto(s)
Antígenos de Diferenciación Mielomonocítica/fisiología , Lectinas/agonistas , Lectinas/antagonistas & inhibidores , Terapia Molecular Dirigida/métodos , Animales , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Antígenos CD/fisiología , Antígenos de Diferenciación de Linfocitos B/fisiología , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Eosinofilia/tratamiento farmacológico , Eosinofilia/fisiopatología , Eosinófilos/efectos de los fármacos , Eosinófilos/fisiología , Humanos , Lectinas/fisiología , Mastocitos/efectos de los fármacos , Mastocitos/fisiología , Mastocitosis/tratamiento farmacológico , Mastocitosis/fisiopatología , Nanopartículas/uso terapéutico , Polisacáridos/farmacología , Polisacáridos/uso terapéutico , Lectinas Similares a la Inmunoglobulina de Unión a Ácido SiálicoRESUMEN
The aim this investigation was to study the changes in the numbers of spleen CD57+ and CD68+ cells (natural killer cells and macrophages respectively) after melatonin administration to the animals kept on different illumination regimens. The experimental animals were given melatonin in dose of 0.03 mg per day for 2 and 4 weeks under conditions of natural illumination or artificial darkening. Spleen paraffin sections were stained using immunohistochemical methods for detection of CD57+ and CD68+ cells. It was shown that long-term administration of melatonin under conditions of natural illumination had an immunosuppressive effect, that was manifested by the depopulation of the marginal zones, white pulp and all the zones of the red pulp, parenchyma loosening and denudation of the reticular stroma of the organ. However, long-term hormone administration under conditions of artificial darkening had an immunostimulatory effect as evidenced by the increased inflow of immunocompetent cells into the spleen, their migration from the white pulp into the marginal zones and emigration into peripheral blood flow, concomitant with the increase in the number of lymphoid nodules. The number of CD57+ and CD68+ cells was increased in splenic periarterial lymphoid sheaths and decreased in B-dependent zones of the organ.
Asunto(s)
Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Luz , Melatonina/administración & dosificación , Animales , Antígenos CD57/efectos de los fármacos , Ritmo Circadiano/efectos de los fármacos , Ritmo Circadiano/fisiología , Células Asesinas Naturales/efectos de los fármacos , Macrófagos/efectos de los fármacos , Masculino , Ratones , Bazo/efectos de los fármacosAsunto(s)
Antineoplásicos/farmacología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Terapia Molecular Dirigida/métodos , Neoplasias/terapia , Linfocitos T/inmunología , Animales , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Quimiocina CCL2/antagonistas & inhibidores , Ensayos Clínicos como Asunto , Progresión de la Enfermedad , Drogas en Investigación/farmacología , Humanos , Factor Estimulante de Colonias de Macrófagos/metabolismo , Macrófagos/inmunología , Ratones , Neoplasias/inmunología , Neoplasias Pancreáticas/terapia , Valor Predictivo de las Pruebas , PronósticoRESUMEN
Wear particle-induced vascularized granulomatous inflammation and subsequent inflammatory osteolysis is the most common cause of aseptic loosening after total joint replacement (TJR); however, the precise mechanism by which this occurs is unclear. This study investigates the effects of the proteasome inhibitor bortezomib (Bzb) on the expression of key biochemical markers of bone metabolism and vascularised granulomatous tissues, such as receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), vascular endothelial growth factor (VEGF) and tumor necrosis factor receptor-associated factor 6 (TRAF6). In addition, the effect of Bzb on apoptosis of CD68+ cells was examined. A total of 32 female BALB/C mice were randomly divided into four groups. After implantation of calvaria bone from syngeneic littermates, titanium (Ti) particles were injected into established air pouches for all mice (excluding negative controls) to provoke inflammatory osteolysis. Subsequently, Bzb was administered at a ratio of 0, 0.1, or 0.5 mg/kg on day 1, 4, 8, and 11 post-surgery to alleviate this response. All of the air pouches were harvested 14 days after the surgical procedure and were processed for molecular and histological analysis. The results demonstrated that Ti injection elevated the expression of RANKL, OPG, VEGF, and TRAF6 at both the gene and protein levels, increased counts of infiltrated cells and thickness of air pouch membranes, and elevated the apoptosis index (AI) of CD68+ cells. Bzb treatment significantly improved Ti particle-induced implanted bone osteolysis, attenuated vascularised granulomatous tissues and elevated AI of CD68+ cells. Therefore, the proteasome pathway may represent an effective therapeutic target for the prevention and treatment of aseptic loosening.
Asunto(s)
Artroplastia de Reemplazo/efectos adversos , Ácidos Borónicos/farmacología , Osteólisis/tratamiento farmacológico , Osteólisis/prevención & control , Inhibidores de Proteasoma/farmacología , Pirazinas/farmacología , Animales , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Apoptosis/efectos de los fármacos , Bortezomib , Femenino , Inflamación/tratamiento farmacológico , Ratones , Ratones Endogámicos BALB C , Osteólisis/inducido químicamente , Osteólisis/inmunología , Osteoprotegerina/biosíntesis , Falla de Prótesis/efectos de los fármacos , Ligando RANK/biosíntesis , Distribución Aleatoria , Factor 6 Asociado a Receptor de TNF/biosíntesis , Titanio , Factores de Crecimiento Endotelial Vascular/biosíntesisRESUMEN
Onionin A (1), a new, stable, sulfur-containing compound, was isolated from acetone extracts of bulbs of onion (Allium cepa), and its structure was characterized as 3,4-dimethyl-5-(1E-propenyl)-tetrahydrothiophen-2-sulfoxide-S-oxide, on the basis of the results of spectroscopic analysis. This compound showed the potential to suppress tumor-cell proliferation by inhibiting the polarization of M2 alternatively activated macrophages.
Asunto(s)
Allium/química , Macrófagos/efectos de los fármacos , Cebollas/química , Sulfóxidos/aislamiento & purificación , Sulfóxidos/farmacología , Tiofenos/aislamiento & purificación , Tiofenos/farmacología , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Humanos , Japón , Receptores de Superficie Celular/efectos de los fármacos , Sulfóxidos/química , Tiofenos/químicaAsunto(s)
Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/inmunología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Obesidad/inmunología , Tiazolidinedionas/farmacología , Diabetes Mellitus Tipo 2/etiología , Femenino , Humanos , Hipoglucemiantes/farmacología , Hipoglucemiantes/uso terapéutico , Interleucina-10/metabolismo , Interleucina-6/metabolismo , Receptores de Lipopolisacáridos/metabolismo , Masculino , Persona de Mediana Edad , Obesidad/complicaciones , Pioglitazona , Tiazolidinedionas/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
As the overall prognosis and treatment response rate to standard chemotherapy for acute myeloid leukemia (AML) remains poor in the older adult population, there is a need for more effective therapeutic agents with lower toxicity profiles that can be offered to these patients. Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that was approved by the US Food and Drug Administration for use as monotherapy in patients 60 years of age and older with relapsed AML. GO consists of a humanized anti-CD33 antibody (hP67.6) which is linked to N-acetyl-gamma calicheamicin 1,2-dimethyl hydrazine dichloride. Once the antibody attaches to the surface antigen, it is rapidly internalized. Calicheamicin, a potent enediyne, is subsequently released and acts as a cytotoxic anti-tumor agent. In this population, GO has an acceptable toxicity and yields response rates approaching 30%. The efficacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated.
Asunto(s)
Aminoglicósidos/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Leucemia Mieloide Aguda/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Aminoglicósidos/administración & dosificación , Aminoglicósidos/farmacología , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales Humanizados , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Antineoplásicos/administración & dosificación , Gemtuzumab , Humanos , Leucemia Mieloide Aguda/epidemiología , Leucemia Mieloide Aguda/fisiopatología , Persona de Mediana Edad , Lectina 3 Similar a Ig de Unión al Ácido Siálico , Estados Unidos/epidemiología , Adulto JovenRESUMEN
BACKGROUND: CD163 is a monocyte/macrophage specific receptor whose soluble form (sCD163) is elevated in inflammatory diseases. Obesity is associated with chronic inflammation and low adiponectin, an anti-inflammatory adipokine. Adiponectin, 5-aminoimidazole-4-carboxamide-1-4-ribofuranoside (AICAR) and metformin activate the AMP-kinase that exerts anti-inflammatory effects, and the influence of adiponectin and these drugs on monocytic CD163 was analysed, and cellular and sCD163 were determined in obesity and type 2 diabetes. MATERIALS AND METHODS: Monocytes were incubated with adiponectin, AICAR or metformin. Furthermore, monocytes and serum were obtained from type 2 diabetic patients (T2D), overweight (defined as a body mass index > or = 25 kg m(-2)) and normal-weight (NW) controls. CD163 was analysed by immunoblot and sCD163 was measured by enzyme-linked immunosorbent assay in the supernatants of the monocytes and in serum. RESULTS: In monocytes, adiponectin reduced cellular and surface CD163, whereas sCD163 was not altered in the corresponding supernatants. Further, metformin and AICAR downregulated CD163. Monocytic CD163 was higher in T2D and obesity, whereas sCD163 in the supernatants was not elevated and neither correlated with serum sCD163 nor systemic adiponectin. There was a positive correlation of monocytic sCD163 with serum but not with monocytic IL-6. In the serum of obese controls and T2D patients, sCD163 was significantly higher compared to NW donors and was positively associated with systemic IL-6. CONCLUSIONS: This study indicates that monocytic CD163 and systemic sCD163 are elevated in T2D and obesity. Adiponectin reduces CD163 in vitro, but additional factors related to obesity like IL-6 may be more relevant in vivo.
Asunto(s)
Adiponectina/administración & dosificación , Aminoimidazol Carboxamida/análogos & derivados , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Hipoglucemiantes/administración & dosificación , Metformina/administración & dosificación , Obesidad/metabolismo , Receptores de Superficie Celular/efectos de los fármacos , Ribonucleótidos/administración & dosificación , Adiponectina/farmacología , Adulto , Aminoimidazol Carboxamida/administración & dosificación , Aminoimidazol Carboxamida/farmacología , Antígenos CD/genética , Antígenos de Diferenciación Mielomonocítica/genética , Diabetes Mellitus Tipo 2 , Regulación hacia Abajo , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Hipoglucemiantes/farmacología , Masculino , Metformina/farmacología , Persona de Mediana Edad , Obesidad/tratamiento farmacológico , Receptores de Superficie Celular/genética , Ribonucleótidos/farmacologíaRESUMEN
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are widely used cholesterol-lowering agents that also possess anti-inflammatory activities. Cysteine-rich 61 (Cyr61) and CCL2 are potential osteolytic mediators in inflammatory bone diseases. The study assessed the effect of simvastatin on tumor necrosis factor alpha (TNF- alpha)-induced synthesis of Cyr61 and CCL2 in MG-63 human osteoblastic cells. The therapeutic effect of simvastatin on rat apical periodontitis was also examined. The synthesis of Cyr61 in MG-63 was assessed by Western analysis. Expression of CCL2 was examined by an enzyme-linked immunosorbent assay. The effect of simvastatin on induced rat periapical lesion was examined radiographically and immunohistochemically. Western blot showed that TNF-alpha stimulated Cyr61 synthesis in MG-63, whereas simvastatin attenuated this effect in a dose-dependent manner. Simvastatin also reduced the levels of TNF-alpha-induced CCL2, and exogenous Cyr61 restored the inhibitory effects. Radiography and histopathology revealed that the administration of simvastatin markedly diminished the severity of induced rat periapical lesions. The numbers of Cyr61-synthesizing osteoblasts and CD-68-positive macrophages were also decreased. Simvastatin suppresses the progression of apical periodontitis, possibly by diminishing Cyr61 expression in osteoblasts and, subsequently, macrophage chemotaxis into the lesions.
Asunto(s)
Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Periodontitis Periapical/tratamiento farmacológico , Simvastatina/uso terapéutico , Pérdida de Hueso Alveolar/diagnóstico por imagen , Pérdida de Hueso Alveolar/tratamiento farmacológico , Animales , Antígenos CD/efectos de los fármacos , Antígenos de Diferenciación Mielomonocítica/efectos de los fármacos , Western Blotting , Recuento de Células , Línea Celular , Quimiocina CCL2/antagonistas & inhibidores , Quimiocina CCL2/efectos de los fármacos , Quimiotaxis/efectos de los fármacos , Proteína 61 Rica en Cisteína/antagonistas & inhibidores , Proteína 61 Rica en Cisteína/efectos de los fármacos , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Inmunohistoquímica , Macrófagos/efectos de los fármacos , Osteoblastos/efectos de los fármacos , Periodontitis Periapical/diagnóstico por imagen , Radiografía Dental Digital , Ratas , Ratas Sprague-Dawley , Simvastatina/farmacología , Factor de Necrosis Tumoral alfa/farmacologíaRESUMEN
There is currently no cure for aseptic loosening (AL) of total joint replacement (TJR) except surgical revision. The purpose of this study was to determine whether oral EM could improve the periprosthetic tissue profiles and reduce serum cytokine production in AL patients who are candidates for surgical revision. We recruited 32 AL patients. AL patients were treated with either EM (600 mg/day, n=18) or placebo (n=14) daily, started one month before surgery and ending on the day of surgery. Blood samples were obtained before EM treatment and during surgery. Periprosthetic tissues and joint fluids were collected during surgery. Our results demonstrate that oral EM reduces the inflammation of periprosthetic tissues, as manifested by the reduction of the numbers of infiltrating cells, CD68+ macrophages, RANKL+ cells, and TRAP+ cells. Remarkable decreases of TNFalpha (9.6-fold), IL-1beta (21.2-fold), and RANKL (76-fold) gene transcripts were observed in periprosthetic tissues of patients treated with oral EM. Serum levels of both TNFalpha and (to a lesser extent) IL-1beta were significantly reduced following EM treatment (p<0.05). Our results suggest that EM represents a biological cure or prevention for those patients who might need repeated revision surgeries and/or show the early signs of progressive osteolysis after TJR.